

Luxembourg, June 2025

Public

Environmental and Social Data Sheet¹

Overview

Project Name: OVERTURE LIFE (IEU TI)
 Project Number: 20250117
 Country: Spain
 Project Description: Overture Life develops innovative products for in vitro fertilisation, aiming to automate processes and make them more effective for successful assisted reproduction technology.

EIA required: no

Invest EU sustainability proofing required: yes

Project included in Carbon Footprint Exercise²: no

(details for projects included are provided in section: “EIB Carbon Footprint Exercise”)

Environmental and Social Assessment

Environmental Assessment

The Promoter is a medical technology company focused on the development and commercialization of products for assisted reproductive technology (ART), focussing on automation of key processes in in vitro fertilisation (IVF), aiming to improve the outcomes of ART.

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project is not listed under Annex I nor Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, so the project is not subject to an EIA Screening or an EIA procedure.

Climate Assessment

Research and development activities, such as those present in this project, neither present significant negative nor positive impacts for climate aspects.

The project has been assessed for Paris alignment and is considered to be aligned both against low carbon and resilience goals against the policies set out in the Climate Bank Roadmap.

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, June 2025

EIB Paris Alignment for Counterparties (PATH) Framework

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Social Assessment

The company's R&D activities and practices comply with relevant national and EU regulations and the Promoter maintains adequate internal procedures and management practices. The company has a sound Occupational Health and Safety policy, including a commitment to comply with legal requirements.

By improving medical techniques which may enhance IVF outcomes, the project has the potential to generate positive social impact.

The project is expected to make a significant contribution to gender equality. The operation will support the development of products that contribute to improved assisted fertility options, treatments and outcomes for both women and men, addressing a public health and social issue in the EU affecting over 25 million people, and with the potential for significant impact on women and men's health and well-being.

Other Environmental and Social Aspects

The Quality Management System (QMS) of the promoter is based on EN ISO 13485:2016 and has been certified by a relevant Notified Body. The QMS is maintained compliant with all MedTech (medical device) related regulations, guidelines, and industry standards.

The clinical trials are conducted in compliance with Regulation (EU) No 536/2014 and the Promoter complies with all the legal standards of anonymisation and data protection.

The Promoter is committed to animal welfare and the responsible use of animals for scientific purposes, ensuring that pre-clinical activities, whether performed directly or by subcontractors, comply with the European Directive 2010/63/EU and/or international equivalent standards on the protection of animals used for scientific purposes, where applicable.

Through the R&D activities and investments, the Promoter is expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Promoter has effective policies and operating procedures in place, which are in line with industry standards. The project concerns investments in research and development for which no significant impact on the environment is expected. The research and development activities of the project do not fall under Annex I nor Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, therefore an EIA is not required.

Sustainability proofing conclusion: The Project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environmental, climate and social information and based on the review of the likely significant environmental, climate and social risks and impacts and the mitigation measures and management systems in place, the Project is deemed to have low residual environmental, climate and social risks and impacts. No further sustainability proofing is therefore required.

Considering the above, the project is considered acceptable for Bank financing in environmental and social terms.